

RESEARCH

Open Access



Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study

Naomi C. A. van der Velden^{1*}, Hanneke W. M. van Laarhoven², Sjaak A. Burgers³, Lizza E. L. Hendriks⁴, Filip Y. F. L. de Vos⁵, Anne-Marie C. Dingemans⁶, Joost Jansen⁶, Jan-Maarten W. van Haarst⁷, Joyce Dits⁸, Ellen MA Smets¹ and Inge Henselmans¹

Abstract

Background: For some patients with advanced cancer not knowing prognosis is essential. Yet, in an era of informed decision-making, the potential protective function of unawareness is easily overlooked. We aimed to investigate 1) the proportion of advanced cancer patients preferring not to know prognosis; 2) the reasons underlying patients' prognostic information preference; 3) the characteristics associated with patients' prognostic information preference; and 4) the concordance between physicians' perceived and patients' actual prognostic information preference.

Methods: This is a cross-sectional study with structured surveys (PROSPECT). Medical and thoracic oncologists included patients ($n = 524$), from seven Dutch hospitals, with metastatic/inoperable cancer and an expected median overall survival of ≤ 12 months. For analysis, descriptive statistics and logistic regression models were used.

Results: Twenty-five to 31% of patients preferred not to know a general life expectancy estimate or the 5/2/1-year mortality risk. Compared to patients preferring to know prognosis, patients preferring unawareness more often reported optimism, avoidance and inability to comprehend information as reasons for wanting *limited* information; and less often reported expectations of others, anxiety, autonomy and a sense of control as reasons for wanting *complete* information. Females ($p < .05$), patients receiving a further line of systemic treatment ($p < .01$) and patients with strong fighting spirit ($p < .001$) were more likely to prefer not to know prognosis. Concordance between physicians' perceived and patients' actual prognostic information preference was poor ($\kappa = 0.07$).

Conclusions: We encourage physicians to explore patients' prognostic information preferences and the underlying reasons explicitly, enabling individually tailored communication. Future studies may investigate changes in patients' prognostic information preferences over time and examine the impact of prognostic disclosure on patients who prefer unawareness.

Keywords: Patient Preference, Prognosis, Physician–patient relations, Communication, Disclosure, Palliative care, Neoplasm metastasis, Cross-sectional studies

Background

Communication of prognosis is important for decision-making in palliative cancer care. It enables patients with advanced cancer to weigh the risks and benefits of treatment, form future care plans and prepare for the end-of-life [1–9]. Still, prognostic unawareness is common

*Correspondence: n.c.vandervelden@amsterdamumc.nl

¹ Department of Medical Psychology, Amsterdam Public Health Research Institute, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Full list of author information is available at the end of the article



[2, 10–13]. Prognostic unawareness could relate to physicians' communication, yet it might also correspond to the approximately 20% of patients preferring not to know prognosis [9, 13–25]. In an era of informed decision-making, the protective function of ignorance is easily overlooked [26].

Not knowing prognosis may be essential for patients as it allows hope [15, 16, 27–31]. Other patients may avoid prognostic estimates out of fear that these evoke negative emotions or become reality [14, 32–36]. Some patients find prognosis too uncertain and therefore useless [9], or feel relieved when not having to understand medical information [37]. Cultural considerations could also motivate patients' wish not to know prognosis [9, 34, 37].

Patients' reasons for preferring prognostic unawareness may be rooted in personal characteristics. Individuals rejecting prognosis to maintain hope might have an optimistic personality and strong fighting spirit [38, 39]. An anxious personality and avoidant coping style could predispose patients' wish to avoid frightful information [30]. Intolerance for uncertainty may underlie patients' aversion to unsure predictions, and limited numeracy skills might explain perceived inability to understand prognostic information [38]. Perhaps, trusting patients prefer to rely on the physician rather than seeking information [40]. Still, relations between patients' prognostic information preference and personal characteristics remain understudied. Besides, while some studies reported associations with older age, female sex and lower income, research investigating the background and clinical characteristics of patients who reject prognosis is scarce [32, 34, 41–44].

Literature indicates that oncologists uncommonly explore patients' information preferences and poorly tailor information [45, 46]. Few studies investigated oncologists' ability to estimate patients' information needs, yet suggest that physicians struggle with judging individuals' prognostic information preferences [25, 47]. This could be problematic, as prognostic non-disclosure impedes decision-making among patients who want information, whereas disclosing prognostic estimates to patients preferring unawareness may cause psychological harm [48].

Thus far, literature has focused on improving prognostic disclosure (e.g., guidelines, training, question prompt lists). Insight into the characteristics and reasons of patients with a preference not to know prognosis, and physicians' knowledge hereof, is necessary to promote tailored communication. Hence, we aimed to investigate the 1) proportion of patients with advanced cancer preferring not to know prognosis; 2) reasons underlying patients' prognostic information preference; 3) characteristics associated with patients' prognostic information preference; and 4) concordance between physicians'

perceived and patients' actual prognostic information preference. For the first aim, we distinguished between a life expectancy estimate (i.e., median overall survival) and the 5-, 2- and 1-year mortality risk. For the subsequent aims, we used the 1-year mortality risk, given its importance for informed decision-making and end-of-life preparation among patients with advanced cancer [49].

Methods

Study design

We conducted a cross-sectional survey study about prognostic information preferences and prognostic awareness among patients with advanced cancer, caregivers and physicians in the Netherlands (PROSPECT: Understanding Prognosis in Palliative Cancer Care, September 2019 – June 2021). For this paper, we used patients' prognostic information preferences as the primary outcomes and excluded caregiver data. This report adheres to the STROBE criteria [50].

Sample and procedure

Medical oncologists and thoracic oncologists (in training) affiliated with seven (non)academic hospitals were invited. Consenting physicians screened patients, whom they had seen at least once, for eligibility consecutively. Eligible patients were ≥ 18 years, had Dutch language proficiency, had an incurable metastatic/inoperable tumor and had an estimated median overall survival of ≤ 12 months at group-level (at diagnosis of advanced disease or after disease progression). Additional file 1 shows eligible tumor types, including treatment type and line. Patients were informed about the study's focus in general terms (i.e., patients' views on illness, treatment and prospects), yet blinded to the prognostic eligibility criteria. Physicians and patients provided written informed consent and participated online or on paper. Procedures complied with the Helsinki Declaration. All institutional and local medical ethics review boards provided exemption from formal approval.

We performed a priori power calculations (α -level = 0.05, power = 0.80, Cohen's $d = 0.5$) to establish differences in patient characteristics (mostly continuous) between patients with and without a preference for prognostic information. We assumed that $\geq 20\%$ of patients preferred prognostic unawareness based on literature [14, 22, 23]. Supposing that physicians play a minimal role in patients' information preferences, we adopted an average cluster size of 10 (patients per physician) and an intraclass correlation of 0.05. The required sample size for the current analyses comprised 331 patients. However, the PROSPECT study was set out to answer multiple research questions, of which some required a larger sample size. We included a sample of > 331 patients to

reach sufficient power for the entire study (see Additional file 2 for configuration of the PROSPECT sample).

Measures

Patients' prognostic information preferences and underlying reasons

We measured patients' preference to know a life expectancy estimate and the 5/2/1-year mortality risk on a binary scale (yes/no) with four adjusted items [22]: "Are you a person who wants to know..." followed by, for example, "the likelihood of dying from your cancer within one year from now?"

We used the 26-item Considerations Concerning Cancer Information Questionnaire (CCCI) to measure patients' reasons for wanting limited information about their disease and treatment (subscales "optimism", "comprehension", "not wanting to be a burden", "avoidance") and complete information about their disease and treatment (subscales "expectations of others", "anxiety", "autonomy", "sense of control") [38]. Items (e.g., "I don't need to know everything because it may frighten me") were scored (1–5, "never" to "always") and averaged per subscale. We included reasons for wanting complete information about disease and treatment to explore all considerations that underlie patients' information preferences and to allow comparison with patients' agreement with reasons for wanting limited information.

Background characteristics

Patients reported their sex (male/female), age, education (low/medium/high), nationality (Dutch/other), religion (Christianity/other/none) and presence of children < 18 years (yes/no).

We measured health literacy with the 3-item Set of Brief Screening Questions (SBSQ-D) [51, 52]. Items (e.g., "How confident are you filling out forms by yourself?") were scored (0–4, "not at all confident" to "extremely confident") and averaged.

We assessed patients' numeracy with the 8-item Subjective Numeracy Scale (SNS) [53]. Items (e.g., "How good are you at working with percentages?") were scored (1–6, "not at all good" to "extremely good") and averaged.

Clinical characteristics

Physicians reported patients' tumor type and line of systemic treatment administered during study participation (none/first/second/ \geq third). The category "none" included patients who might have had systemic treatment prior to study participation and/or may receive systemic treatment in the future. Additionally, patients in the category "none" could have received non-systemic treatment during study participation

(e.g., radiotherapy, best supportive care), yet this was not reported. Physicians registered patients' date of diagnosis of metastatic/inoperable cancer to calculate time since diagnosis.

We measured patients' perceived likelihood of dying within one year with one item: "How likely is it you will die from your cancer within one year from now?" (1–7, "extremely unlikely", "very unlikely", "unlikely", "possibly", "likely", "very likely", "extremely likely"). The "very (un)likely" and "extremely (un)likely" categories were combined in the analyses to reduce the number of statistical comparisons.

We assessed health-related quality of life with the 2-item Global Health Status subscale (GHS) of the EORTC Quality of Life Questionnaire (EORTC-QLQ-C30) [54]. Items (i.e., "How would you rate your overall 1) health and 2) quality of life during the past week?") were scored (1–7, "very poor" to "excellent"). Scores were transformed to a 0–100 scale.

Personal characteristics

We measured fighting spirit (i.e., viewing cancer as a challenge) with the 4-item fighting spirit subscale of the Mini Mental Adjustment to Cancer (mini-MAC) scale [55]. Items (e.g., "I am determined to beat this disease") were scored (1–4, "does not apply at all to me" to "totally applies to me") and summed.

We assessed trait optimism with the 10-item Life Orientation Test-Revised (LOT-R) [56]. Six items (e.g., "I'm always optimistic about my future") were scored (0–4, "strongly disagree" to "strongly agree") and summed, as the others were filler items.

We measured trait anxiety (i.e., stable aspects of proneness to anxiety) with the 20-item trait scale of the Spielberger State and Trait Anxiety Inventory (STAI) [57]. Items (e.g., "I feel nervous and restless") were scored (1–4, "not at all" to "very much so") and summed.

We assessed avoidance coping with the 8-item avoidance subscale of the Utrecht Coping List (UCL) [58]. Items (e.g., "Avoiding difficult situations") were scored from (1–4, "never" to "very often") and summed.

We measured uncertainty tolerance (i.e., perceiving ambiguous situations as desirable) [59] with the 7-item Tolerance for Ambiguity (TFA) [60]. Items (e.g., "If I am uncertain about the responsibilities involved in a particular task, I get very anxious") were scored (1–6, "strongly agree" to "strongly disagree") and summed.

We assessed patients' trust in the physician with the 5-item Trust in Oncologist Scale-Short Form (TiOS-SF) [61]. Items (e.g., "All in all, you have complete trust in your doctor") were scored (1–5, "strongly disagree" to "strongly agree") and averaged.

Physicians' perceptions of patients' prognostic information preference

Physicians reported their perception of each patient's prognostic information preference with an adjusted item [22]: "Is this patient a person who wants to know the likelihood of him/her dying within one year from now?" Physicians answered: "Yes, I think so" or "No, I don't think so".

Statistical analysis

We used IBM SPSS Statistics 26 for all analyses. Missing data were reported and not imputed. To present patients' prognostic information preferences (i.e., life expectancy estimate; 5/2/1-year mortality risk), we used descriptive statistics. We described the agreement with reasons for wanting limited and complete information for patients with and without a preference to know the 1-year mortality risk separately and compared means (T-tests).

To investigate differences between patients with and without a preference to know the 1-year mortality risk in patient characteristics, we performed T-tests and Chi²-tests. We examined clustering of data within physicians (intraclass correlation $\geq 10\%$), indicating a need for multilevel analysis [62–64].

To examine if patients' information preference regarding the 1-year mortality risk (0 = preferring to know, 1 = preferring not to know) related to patient characteristics, we constructed a logistic regression model. Intercorrelations between independent variables were calculated to identify multicollinearity ($r > 0.80$) [65]. We entered variables in the multivariate model one by one, hierarchically (i.e., background, clinical, personal). After each entry, we evaluated variables at a liberal α -level ($p < 0.20$), preventing elimination due to confounding or modification effects. We tested the resultant model with an α -level of $p < 0.05$. We eliminated non-significant variables one by one to simplify the final model.

To present the concordance between physicians' perceived and patients' actual information preference regarding the 1-year mortality risk, we calculated kappa values (poor, < 0.20 ; fair, $0.21–0.40$; moderate, $0.41–0.60$; good, $0.61–0.80$; very good, $0.81–1.00$) [66].

Results

PROSPECT included 540 patients and/or caregivers (response rate 62%; see Additional file 2), of whom 524 patients reported their prognostic information preferences. Patients were consulted by $n = 33$ medical oncologists and $n = 21$ thoracic oncologists ($M_{\text{included patients}} = 20$). About half of patients was male; the mean age was 64 years (Table 1). Table 2 presents characteristics of patients with and without a preference to know the 1-year mortality risk.

Patients' prognostic information preferences and underlying reasons

One-fourth of patients (25%, $n = 128/522$) preferred not to know a general life expectancy estimate. The proportion of patients preferring unawareness of the mortality risk numerically increased as the indicated period shortened (5/2/1-year); 31% preferred not to know the 1-year mortality risk (Fig. 1).

Patients preferring not to know the 1-year mortality risk showed significantly stronger agreement with most reasons for wanting limited information than patients preferring to know (i.e., staying optimistic, avoiding frightful information, feeling unable to comprehend information). Overall, patients preferring not to know the 1-year mortality risk agreed most strongly with wanting limited information to stay optimistic. The total sample least endorsed "not wanting to be a burden to the physician" as a reason to prefer limited information (Table 3).

Contrastingly, patients preferring not to know the 1-year mortality risk showed significantly less agreement with reasons for wanting complete information than patients preferring to know (i.e., gaining a sense of control, meeting expectations of others, reducing anxiety, gaining autonomy). Remarkably, patients preferring not to know prognosis agreed significantly more strongly with reasons for wanting *complete* information than with reasons for wanting *limited* information (Table 3).

Characteristics related to patients' prognostic information preference

Univariate tests showed that females compared to males, and low educated compared to high-educated patients, were significantly more likely to prefer not knowing the 1-year mortality risk. Patients receiving a second or \geq third line of systemic treatment at the time of study participation were more likely to prefer unawareness than patients without systemic treatment. Similarly, patients receiving a \geq third line of systemic treatment at the time of study participation were significantly more likely to prefer unawareness than patients receiving a first line. Patients perceiving the likelihood of dying within one year as extremely unlikely were more likely to prefer not knowing the 1-year mortality risk than patients perceiving this chance as more likely. The same holds for patients perceiving the likelihood of dying within one year as possible compared to patients perceiving this chance as extremely likely. Patients preferring not to know the 1-year mortality risk had significantly lower numeracy skills, better health-related quality of life, less trait anxiety and stronger fighting spirit than patients preferring to know (Table 2). Patients' age, nationality, religion, presence of children < 18 years, health literacy, tumor type, time since diagnosis, trait optimism, avoidance coping,

Table 1 Background, clinical and personal characteristics of the total sample

Patient characteristics	Cronbach's alpha ^a	Total sample n = 524
Sex (male), % (n)		54.8 (287)
Age (years), mean ± SD		63.9 ± 11.0
Education, % (n) ^b		
Low		37.9 (198)
Medium		26.6 (139)
High		35.4 (185)
Health literacy (SBSQ-D, 0–4), mean ± SD ^c	.71	3.2 ± 0.8
Numeracy (SNS, 1–6), mean ± SD ^d	.90	4.2 ± 1.2
Nationality (Dutch), % (n)		95.4 (500)
Religion, % (n)		
None		59.0 (309)
Christianity		37.0 (194)
Other ^e		4.0 (21)
Presence of children < 18, % (n) ^f		10.3 (54)
Time since diagnosis (months), mean ± SD ^g		17.8 ± 21.5
Line of systemic treatment during study participation, % (n) ^h		
None		23.6 (121)
First line		43.5 (223)
Second line		20.1 (103)
≥ Third line		12.9 (66)
Tumor type, % (n) ^d		
Lung		24.1 (125)
Pleura		6.0 (31)
Oesophagogastric		13.7 (71)
Pancreatic		6.9 (36)
Other gastrointestinal		14.9 (77)
Colorectal		2.9 (15)
Brain		11.8 (61)
Gynaecological		9.5 (49)
Soft tissue		2.7 (14)
Other (each type n < 10) ⁱ		7.5 (39)
Patients' perceived likelihood of dying in one year, % (n) ^j		
Very to extremely unlikely		24.3 (125)
Unlikely		10.5 (54)
Possibly		36.4 (187)
Likely		7.8 (40)
Very to extremely likely		21.0 (108)
Health-related quality of life (GHS, 0–100), mean ± SD ^f	.88	63.0 ± 21.0
Fighting spirit (mini-MAC, 4–16), mean ± SD ^k	.67	11.5 ± 2.7
Trait optimism (LOT-R, 0–24), mean ± SD ^g	.73	14.6 ± 3.9
Trait anxiety (STAI-trait, 20–80), mean ± SD ^g	.94	39.7 ± 10.7

Table 1 (continued)

Patient characteristics	Cronbach's alpha ^a	Total sample n = 524
Avoidance coping (UCL, 8–32), mean ± SD ^l	.72	15.5 ± 3.3
Uncertainty tolerance (TFA, 7–42), mean ± SD ^l	.71	25.8 ± 5.9
Trust in the physician (TiOS-SF, 1–5), mean ± SD ^g	.92	4.3 ± 0.7

^a Interpretation: < 0.50 unacceptable, 0.50–0.60 poor, 0.60–0.70 questionable, 0.70–0.80 acceptable, 0.80–0.90 good, 0.90–1.00 excellent

^b n = 522/524 (2 missing). Low vocational education; medium level vocational education; high vocational or academic education

^c n = 515/524 (9 missing)

^d n = 518/524 (6 missing)

^e Including Islam, Buddhism, Hinduism, Judaism, Humanism, spirituality and "own belief"

^f n = 523/524 (1 missing)

^g n = 517/524 (7 missing)

^h n = 513/524 (11 missing)

ⁱ Including melanoma, head and neck, thyroid, breast, vagina, prostate, bladder, kidney, adrenal cortex, bone, carcinoid and unknown primary tumors

^j n = 514/524 (10 missing)

^k n = 511/524 (13 missing)

^l n = 516/524 (8 missing)

n Sample size, SD Standard deviation, SBSQ-D Set of Brief Screening Questions-Dutch, SNS Subjective Numeracy Scale, GHS Global Health Status from the EORTC-QLQ-C30, EORTC-QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer, MAC Mental Adjustment to Cancer, LOT-R Life Orientation Test-Revised, STAI Spielberger State and Trait Anxiety Inventory, UCL Utrecht Coping List, TFA Tolerance for Ambiguity, TiOS-SF Trust in Oncologist Scale-Short Form

uncertainty tolerance and trust in the physician were not related to information preference regarding the 1-year mortality risk.

In the multivariate analysis, females (OR = 1.67, 95%CI [1.12; 2.48], p < 0.05) were significantly more likely to prefer not knowing the 1-year mortality risk than males. Patients receiving a ≥ third line of systemic treatment at the time of study participation were significantly more likely to prefer not knowing the 1-year mortality risk than patients receiving a first line (OR = 0.499, 95%CI [0.275; 0.906], p < 0.05) or without systemic treatment (OR = 0.375, 95%CI [0.190; 0.742], p < 0.01). Additionally, patients with stronger fighting spirit (OR = 1.22, 95%CI [1.13; 1.33], p < 0.001) were more likely to prefer not knowing the 1-year mortality risk (Table 4).

Concordance between physicians' perceived and patients' actual prognostic information preference

Physicians' perceptions of and patients' actual preference for information about the 1-year mortality risk corresponded in 55% of cases (n = 285/518) (Table 5). Among patients preferring not to know the 1-year mortality risk, 50% (n = 81/161) had a treating physician who accurately reported their information preference; among patients

Table 2 Background, clinical and personal characteristics of patients with and without a preference to know prognosis

Patient characteristics	Patients preferring not to know 1-year mortality risk (30.7%) <i>n</i> = 161/524	Patients preferring to know 1-year mortality risk (69.3%) <i>n</i> = 363/524
Sex, % (<i>n</i>) **		
Male	25.4 (73) ¹	74.6 (214)
Female	37.1 (88) ²	62.9 (149)
Age (years), mean ± SD	64.3 ± 10.6	63.7 ± 11.2
Education, % (<i>n</i>) ^{a *}		
Low	37.4 (74) ¹	62.6 (124)
Medium	27.3 (38) ^{1,2}	72.7 (101)
High	26.5 (49) ²	73.5 (136)
Health literacy (SBSQ-D, 0–4), mean ± SD ^b	3.2 ± 0.8	3.3 ± 0.8
Numeracy (SNS, 1–6), mean ± SD ^{c *}	4.0 ± 1.1	4.3 ± 1.2
Nationality (Dutch), % (<i>n</i>)	95.7 (154)	95.3 (346)
Religion, % (<i>n</i>)		
None	28.5 (88)	71.5 (221)
Christianity	33.0 (64)	67.0 (130)
Other ^d	42.9 (9)	57.1 (12)
Presence of children < 18, % (<i>n</i>) ^e		
Yes	31.5 (17)	68.5 (37)
No	32.3 (121)	67.7 (254)
Time since diagnosis (months), mean ± SD ^f	20.3 ± 23.5	16.7 ± 20.5
Line of systemic treatment during study participation, % (<i>n</i>) ^{g **}		
None	22.3 (27) ¹	77.7 (94)
First line	29.1 (65) ^{1,2}	70.9 (158)
Second line	38.8 (40) ^{2,3}	61.2 (63)
≥ Third line	43.9 (29) ³	56.1 (37)
Tumor type, % (<i>n</i>) ^c		
Lung	31.2 (39)	68.8 (86)
Pleura	25.8 (8)	72.4 (23)
Oesophagogastric	15.5 (11)	84.5 (60)
Pancreatic	22.2 (8)	77.8 (28)
Other gastrointestinal	35.1 (27)	64.9 (50)
Colorectal	33.3 (5)	66.7 (10)
Brain	36.1 (22)	63.9 (39)
Gynaecological	40.8 (20)	59.2 (29)
Soft tissue	42.9 (6)	57.1 (8)
Other (each type <i>n</i> < 10) ^h	38.5 (15)	61.5 (24)
Patients' perceived likelihood of dying in one year, % (<i>n</i>) ^{i ***}		
Very to extremely unlikely	44.8 (56) ¹	55.2 (69)
Unlikely	24.1 (13) ^{2,3}	75.9 (41)
Possibly	31.0 (58) ³	69.0 (129)
Likely	22.5 (9) ^{2,3}	77.5 (31)
Very to extremely likely	20.4 (22) ²	79.6 (86)

Table 2 (continued)

Patient characteristics	Patients preferring not to know 1-year mortality risk (30.7%) <i>n</i> = 161/524	Patients preferring to know 1-year mortality risk (69.3%) <i>n</i> = 363/524
Health-related quality of life (GHS, 0–100), mean ± SD ^{e **}	66.7 ± 20.9	61.4 ± 20.8
Fighting spirit (mini-MAC, 4–16), mean ± SD ^{j ***}	12.3 ± 2.4	11.1 ± 2.8
Trait optimism (LOT-R, 0–24), mean ± SD ^f	15.1 ± 4.2	14.4 ± 3.7
Trait anxiety (STAI-trait, 20–80), mean ± SD ^{f *}	38.2 ± 10.7	40.4 ± 10.6
Avoidance coping (UCL, 8–32), mean ± SD ^k	15.8 ± 3.3	15.4 ± 3.3
Uncertainty tolerance (TFA, 7–42), mean ± SD ^k	26.1 ± 5.9	25.7 ± 5.9
Trust in the physician (TIOS-SF, 1–5), mean ± SD ^f	4.3 ± 0.6	4.3 ± 0.7

^{1,2,3} Proportions with similar superscripted numbers do not differ significantly from each other ($\alpha = .05$)

^a *n* = 522/524 (2 missing). Low vocational education; medium level vocational education; high vocational or academic education

^b *n* = 515/524 (9 missing)

^c *n* = 518/524 (6 missing)

^d Including Islam, Buddhism, Hinduism, Judaism, Humanism, spirituality and "own belief"

^e *n* = 523/524 (1 missing)

^f *n* = 517/524 (7 missing)

^g *n* = 513/524 (11 missing)

^h Including melanoma, head and neck, thyroid, breast, vagina, prostate, bladder, kidney, adrenal cortex, bone, carcinoid and unknown primary tumors

ⁱ *n* = 514/524 (10 missing)

^j *n* = 511/524 (13 missing)

^k *n* = 516/524 (8 missing)

* Significant at $p < .05$. ** Significant at $p < .01$. *** Significant at $p < .001$


n Sample size, *SD* Standard deviation, *SBSQ-D* Set of Brief Screening Questions-Dutch, *SNS* Subjective Numeracy Scale, *GHS* Global Health Status from the EORTC-QLQ-C30, *EORTC-QLQ-C30* European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer, *MAC* Mental Adjustment to Cancer, *LOT-R* Life Orientation Test-Revised, *STAI* Spielberger State and Trait Anxiety Inventory, *UCL* Utrecht Coping List, *TFA* Tolerance for Ambiguity, *TIOS-SF* Trust in Oncologist Scale-Short Form

preferring to know, this was 57% (*n* = 204/357). The calculated kappa value of 0.066 suggests poor concordance between physicians and patients.

Discussion

Main findings

We found that 25% of patients prefer not to know a general life expectancy estimate, increasing up to 31% as the indicated period shortens (5/2/1-year). Our univariate results indicate that patients with difficulties in



understanding medical information and those feeling relatively well may be more likely to prefer prognostic unawareness. Moreover, psychological factors likely underlie patients' information preference, given the lower levels of anxiety and stronger fighting spirit among patients

preferring not to know. Besides fighting spirit, female sex and a further line of systemic treatment were associated with preferring prognostic unawareness in univariate and multivariate analyses. Importantly, physicians often did not know patients' prognostic information preference.

Table 3 Reasons for wanting limited or complete information about disease and treatment for patients with and without a preference to know prognosis

Reasons	Cronbach's alpha ^a	Patients preferring not to know 1-year mortality risk ^b n = 161/524 mean ± SD	Patients preferring to know 1-year mortality risk n = 363/524 mean ± SD
Reasons for wanting limited information			
Staying optimistic (CCCI, 1–5) ^c	.87	3.4 ± 1.1***	2.3 ± 1.1
Avoiding frightful information (CCCI, 1–5) ^c	.89	2.5 ± 1.1***	1.8 ± 0.9
Feeling unable to comprehend information (CCCI, 1–5) ^d	.85	1.9 ± 0.9*	1.7 ± 0.9
Not wanting to be a burden to the physician (CCCI, 1–5) ^c	.89	1.6 ± 0.8	1.6 ± 0.9
Reasons for wanting complete information			
Gaining a sense of control (CCCI, 1–5) ^e	.86	3.4 ± 1.1	4.2 ± 0.9***
Meeting expectations of others (CCCI, 1–5) ^f	.79	2.1 ± 1.1	2.4 ± 1.3**
Reducing anxiety (CCCI, 1–5) ^e	.85	2.5 ± 1.1	2.9 ± 1.3***
Gaining autonomy (CCCI, 1–5) ^f	.71	2.6 ± 1.0	3.1 ± 1.1***

^a Interpretation: < 0.50 unacceptable, 0.50–0.60 poor, 0.60–0.70 questionable, 0.70–0.80 acceptable, 0.80–0.90 good, 0.90–1.00 excellent

^b Patients preferring not to know agreed more strongly with reasons for wanting complete information than with reasons for wanting limited information (MD = .33; p = .001)

^c n = 522/524 (2 missing)

^d n = 521/524 (3 missing)

^e n = 518/524 (6 missing)

^f n = 517/524 (7 missing)

* Significant at p < .05. ** Significant at p < .01. *** Significant at p < .001

SD Standard deviation, CCCI Considerations Concerning Cancer Information Questionnaire, MD Mean difference

Table 4 Logistic regression model with predictors of patients’ preference not to know prognosis^a

Predictor	Final model ^{b,c}						
	B	SE	Wald	p	Exp(b)	Lower CI	Upper CI
Constant	-2.869	.559	26.390	.000***	.057		
Sex	.511	.203	6.361	.012*	1.667	1.121	2.480
Line of systemic treatment during study participation							
None	-.980	.347	7.958	.005**	.375	.190	.742
First line	-.694	.304	5.225	.022*	.499	.275	.906
Second line	-.154	.336	.210	.647	.857	.444	1.656
≥ Third line (ref)			12.072	.007**			
Fighting spirit (mini-MAC)	.202	.041	24.725	.000***	1.224	1.130	1.326

^a 0 = preferring to know the 1-year mortality risk, 1 = preferring not to know the 1-year mortality risk

^b n = 505/524 (19 missing)

^c Multilevel analysis was not required, since accounting for clustering within physicians by adding a level did not significantly improve model fit ($p > .05$) and the intraclass correlation was low (0.05). Intercorrelations between predictors were $r < .60$. Patients’ age, nationality, religion, presence of children < 18 years, health literacy, numeracy, tumor type, time since diagnosis, trait optimism, trait anxiety, avoidance coping, uncertainty tolerance and trust in the physician were omitted from the model ($p > .20$). To simplify the final model, educational level, patients’ estimation of the likelihood of dying within one year and health-related quality of life ($p > .05$) were eliminated

* Significant at $p < .05$. ** Significant at $p < .01$. *** Significant at $p < .001$

B Unstandardized coefficient, SE Standard error, p significance, Exp(b) exponentiation of the B coefficient, which is an odds ratio, CI 95% 95% Confidence Interval, ref Reference category, MAC Mental Adjustment to Cancer

Table 5 Concordance between physicians’ perceived and patients’ actual preference to know prognosis

Physicians’ perceived information preference ^a	Patients preferring not to know 1-year mortality risk % (n)	Patients preferring to know 1-year mortality risk % (n)	Total
Patient prefers not to know	50.3 (81) ^b	42.9 (153) ^c	234
Patient prefers to know	49.7 (80) ^c	57.1 (204) ^b	284
Total	100 (161)	100 (357)	518

^a n = 518/524 (6 missing)

^b Concordance between physicians’ perceived and patients’ actual preference for information about the 1-year mortality risk

^c Discordance between physicians’ perceived and patients’ actual preference for information about the 1-year mortality risk

n Sample size

What this study adds

This study is the first to reveal the association between fighting spirit and patients’ prognostic information preference. Perhaps, patients with strong fighting spirit benefit from unawareness, as it enables them to keep hope and push through [28]. Congruently, patients preferring not to know prognosis more often reported optimism, known to relate to fighting spirit, as a reason for wanting limited information [67]. Still, physicians should evaluate the adaptiveness of patients’ prognostic unawareness based on strong fighting spirit, since it may obstruct anticipation of the end-of-life [9, 68]. Considering that patients’ readiness for prognostic discussions could evolve over time, physicians may need to explore patients’ prognostic information preferences repeatedly (e.g., “Some people like to know everything about their illness and what may happen in the future, others prefer

not to know too many details. How much would you like to know about your prognosis right now?”; “With regards to your prognosis, have I given you the information you need so far?”) [69–72]. While a patient’s unchanged preference for unawareness should be respected, physicians can consider negotiating for limited prognostic disclosure to assure informed decisions about the best possible (future) care [24, 69]. Another approach is to discuss planning for *hypothetical* deterioration, hereby gaining insight into patients’ wishes without disclosing prognostic estimates [73].

Interestingly, we observed that patients who prefer not to know prognosis generally showed stronger agreement with reasons for wanting complete *versus* limited information. Apparently, patients who prefer prognostic unawareness recognize the relevance of acquiring medical information to, for example, gain a sense of control.

This result might exhibit ambivalent attitudes towards prognostic communication, as patients often struggle between wanting clarity and needing hope [16, 24, 74, 75]. The observed ambivalence seems to discourage dichotomization of information preferences (yes/no). Hence, physicians may explain the various types and formats of prognostic information they can offer (e.g., life expectancy, mortality risk, likelihood of experiencing events; point estimates, time frames, multiple scenarios; words, numbers) [14, 22, 24, 71, 76].

We found that females were more likely to prefer not knowing prognosis than males. Conflictingly, previous research shows that females are more likely to report having discussed prognosis and to understand their disease stage, which demands further research on sex differences [77, 78]. In our study, females' preference for prognostic unawareness might be (partially) attributed to confounding variables, as females were significantly more often low-educated, had lower numeracy skills, were more likely to receive a further line of systemic treatment and reported better health-related quality of life than males. Reviewing the association between patients' ongoing line of systemic treatment and preference not to know prognosis, we observed that patients receiving a further line relatively more often believed that dying within one year was unlikely. Still, the causal direction of these relations remains unclear.

The concordance between physicians' perceived and patients' actual prognostic information preference was nearly the same as would be expected by chance, emphasizing the importance of explicit assessment of individuals' prognostic information preferences [22, 25, 47]. Possibly, physicians did not standardly explore patients' information needs, which could relate to reluctance towards prognostic conversations [25, 37, 47, 79–81]. However, we must interpret the poor concordance cautiously. Physician–patient contact may have been limited, as some patients were consulted by multiple physicians and participation was not linked to a specific moment in the disease trajectory. Besides, physicians were unable to report not knowing patients' preference.

Strengths and limitations

Firstly, a selection bias potentially occurred as patients who strongly avoid threatening information might have been more likely to decline participation, which could cause an underestimation of the proportion of patients preferring not to know prognosis. Moreover, the study's generalizability is limited to the Dutch population, which is Western, largely non-religious and known for its straightforwardness. Hence, the wish not to know prognosis might be even more pronounced in other countries.

Our sample is also relatively young and certain tumor types are underrepresented. Both age and tumor type were however unrelated to patients' prognostic information preference. Another limitation concerns the inclusion of a larger sample than planned, which may have led to statistically significant findings that lack clinical relevance. As a definition of minimal clinically important differences in this study's setting is missing, drawing conclusions about clinical relevance is complicated regardless of sample size. Lastly, the validity and reliability of non-standardized survey items are unknown, and our cross-sectional dichotomous measurement of prognostic information preferences paints a limited picture. Future research could examine changes in patients' prognostic information preferences over time and investigate the impact of prognostic disclosure on patients who prefer unawareness. Furthermore, there is a need for evidence-based clinical guidelines about how to explore patients' prognostic information preferences and discuss prognosis effectively. Strengths pertain to the measurement of patients' preferences regarding different types of prognostic information, and physicians' perceptions hereof, among a relatively large sample of advanced cancer patients.

Conclusions

We showed that, in a Western secularized country, a substantial proportion of patients prefer not to know prognosis. This points out the universality of a wish for prognostic unawareness. Although the underlying reasons vary and could be ambivalent, patients' preference not to know prognosis seems mainly motivated by a need for optimism. Concordance between physicians' perception of and patients' actual prognostic information preference was poor. We encourage physicians to assess patients' prognostic information preferences and explore their motivations explicitly and repeatedly, rather than making assumptions based on patient characteristics shown to relate to prognostic information preferences [14, 71, 82]. Physicians can explain the variety in type and detail of prognostic information they can offer to promote individually tailored communication [71].

Abbreviations

B: Unstandardized coefficient; CCCL: Considerations Concerning Cancer Information Questionnaire; CI95%: 95% Confidence Interval; EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer; Exp(b): Exponentiation of the B coefficient, which is an odds ratio; GHS: Global Health Status; LOT-R: Life Orientation Test-Revised; MAC: Mental Adjustment to Cancer; MD: Mean difference; *n*: Sample size; OR: Odds ratio; *p*: Significance; Ref: Reference category; SBSQ-D: Set of Brief Screening Questions-Dutch; SD: Standard deviation; SE: Standard error; SNS: Subjective Numeracy Scale; STAI: Spielberger State and Trait Anxiety Inventory; TFA: Tolerance for Ambiguity; TIOS-SF: Trust in Oncologist Scale-Short Form; UCL: Utrecht Coping List.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12885-022-09911-8>.

Additional file 1. Overview of eligible tumor types, specified by non-treated and treated cancer. This overview is not inclusive. Physicians could include patients with other tumor types, for whom the general inclusion criteria were applicable (≥ 18 years, Dutch language proficiency, diagnosis of metastatic or locally inoperable cancer at least two months before participation, not eligible for therapy with curative intent, median survival of 12 months or less on group-level). Patients could participate when receiving anticancer therapy or comfort care.

Additional file 2. Flowchart showing inclusion, exclusion and response of the PROSPECT study.

Acknowledgements

The authors would like to thank all participating physicians and patients from the Amsterdam University Medical Centers, Maastricht University Medical Center+, Antoni van Leeuwenhoek Ziekenhuis, Tergooi Ziekenhuis, University Medical Center Utrecht, Erasmus Medical Center and Franciscus Gasthuis & Vlietland Ziekenhuis. We also thank Maartje Meijers, Rania Ali, Laura Streefkerk and Nora Looze for their assistance in this study's data collection.

Authors' contributions

NV: study concept and design, data acquisition, quality control of data, data analysis and interpretation, writing and editing the manuscript. HL: study concept and design, data acquisition, quality control of data, reviewing and editing the manuscript. SB, LH, FV, AD, JJ, JH, JD: data acquisition, reviewing and editing the manuscript. ES: study concept and design, quality control of data, interpretation, reviewing and editing the manuscript. IH: original research proposal and funding application, study concept and design, quality control of data, data analysis and interpretation, reviewing and editing the manuscript. All authors read and approved the final manuscript.

Funding

The authors disclosed receipt of financial support by the Dutch Cancer Society [grant number 11547] for the research of this article. The funder was not involved in the study design, data collection, data analyses, data interpretation or report of the article.

Availability of data and materials

The datasets analyzed during the current study are not publicly available due to ethical considerations, but are available from the corresponding author on reasonable request. Additional files for this article, including a flowchart showing inclusion, exclusion and response of the PROSPECT study and an overview of eligible tumor types (specified by non-treated and treated cancer) is available online.

Declarations

Ethics approval and consent to participate

The study was granted exemption from formal approval by the Amsterdam University Medical Centers Institutional Medical Ethics Review Board (W19_051#19.073, 14th of February 2019), the Medical Research Ethics Committee academisch ziekenhuis Maastricht, Maastricht University (METC 2019-1146, 8th of May 2019), the Institutional Review Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital (19.228/IRBd19152-M19PCC, 19th of July 2019), the Hospital Board of Tergooi Ziekenhuis (Kv/19.035, 1st of August, 2019), the Medical Research Ethics Committee Utrecht (WAG/mb/19/027709, 7th of August 2019), the Daily Board of the Medical Ethics Committee Erasmus MC (MEC-2020-0529, 9th of July 2020) and the Hospital Board of Franciscus Gasthuis & Vlietland Ziekenhuis (T110/2020-084, 15th of July 2020).

All methods were carried out in accordance with the Helsinki Declaration. We informed study participants orally about the study and provided them written information about participation, including the study's purpose, procedures, risks and benefits, data management and privacy. All study participants provided written informed consent on voluntary basis only.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Medical Psychology, Amsterdam Public Health Research Institute, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. ²Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Maastricht, The Netherlands. ³Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands. ⁴Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands. ⁵Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ⁶Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁷Department of Respiratory Medicine and Department of Surgery, Tergooi Ziekenhuis, Hilversum, The Netherlands. ⁸Department of Pulmonology, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands.

Received: 22 March 2022 Accepted: 14 July 2022

Published online: 01 September 2022

References

- Enzinger AC, Zhang B, Schrag D, Prigerson HG. Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer. *J Clin Oncol*. 2015;33(32):3809–16.
- Weeks JC, Cook EF, O'Day SJ, Petersen LM, Wenger N, Reding D, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. *JAMA*. 1998;279(21):1709–14.
- Francke AL, Willems DL. Terminal patients' awareness of impending death: the impact upon requesting adequate care. *Cancer Nurs*. 2005;28(3):241–7.
- Edmonds P, Rogers A. 'If only someone had told me ...' A review of the care of patients dying in hospital. *ClinMed*. 2003;3(2):149–52.
- Epstein AS, Prigerson HG, O'Reilly EM, Maciejewski PK. Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer. *J Clin Oncol*. 2016;34(20):2398–403.
- Walling A, Lorenz KA, Dy SM, Naeim A, Sanati H, Asch SM, et al. Evidence-based recommendations for information and care planning in cancer care. *J Clin Oncol*. 2008;26(23):3896–902.
- Hallen SA, Hootsmans NA, Blaisdell L, Gutheil CM, Han PK. Physicians' perceptions of the value of prognostic models: the benefits and risks of prognostic confidence. *Health Expect*. 2015;18(6):2266–77.
- Walczak A, Henselmans I, Tattersall MH, Clayton JM, Davidson PM, Young J, et al. A qualitative analysis of responses to a question prompt list and prognosis and end-of-life care discussion prompts delivered in a communication support program. *Psychooncology*. 2015;24(3):287–93.
- Ahalt C, Walter LC, Yourman L, Eng C, Perez-Stable EJ, Smith AK. "Knowing is better": preferences of diverse older adults for discussing prognosis. *J Gen Intern Med*. 2012;27(5):568–75.
- Wen F-H, Chen J-S, Chang W-C, Chou W-C, Hsieh C-H, Tang ST. Accurate prognostic awareness and preference states influence the concordance between terminally ill cancer patients' states of preferred and received life-sustaining treatments in the last 6 months of life. *Palliat Med*. 2019;33(8):1069–79.
- Trevino KM, Zhang BH, Shen MJ, Prigerson HG. Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information. *Cancer*. 2016;122(12):1905–12.
- Mack JW, Walling A, Dy S, Antonio ALM, Adams J, Keating NL, et al. Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer. *Cancer*. 2015;121(11):1891–7.
- Liu PH, Landrum MB, Weeks JC, Huskamp HA, Kahn KL, He YL, et al. Physicians' Propensity To Discuss Prognosis Is Associated with

- Patients' Awareness of Prognosis for Metastatic Cancers. *J Palliat Med.* 2014;17(6):673-674.
14. Innes S, Payne S. Advanced cancer patients' prognostic information preferences: a review. *Palliat Med.* 2009;23(1):29-39.
 15. Helft PR. Necessary collusion: prognostic communication with advanced cancer patients. *J Clin Oncol.* 2005;23(13):3146-50.
 16. Kirk P, Kirk I, Kristjanson LJ. What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study. *BMJ.* 2004;328(7452):1343.
 17. Walczak A, Henselmans I, Tattersall MH, Clayton JM, Davidson PM, Young J, et al. A qualitative analysis of responses to a question prompt list and prognosis and end-of-life care discussion prompts delivered in a communication support program. *Psychooncology.* 2015;24(3):287-93.
 18. de Haes H. Dilemmas in patient centeredness and shared decision making: A case for vulnerability. *Patient Educ Couns.* 2006;62(3):291-8.
 19. Deschepper R, Bernheim JL, Vander SR, Van den Block L, Michiels E, Van Der Kelen G, et al. Truth-telling at the end of life: a pilot study on the perspective of patients and professional caregivers. *Patient Educ Couns.* 2008;71(1):52-6.
 20. Meredith C, Symonds P, Webster L, Lamont D, Pyper E, Gillis CR, et al. Information needs of cancer patients in west Scotland: Cross sectional survey of patients' views. *BMJ.* 1996;313(7059):724-6.
 21. Friis LS, Elverdam B, Schmidt KG. The patient's perspective - A qualitative study of acute myeloid leukaemia patients' need for information and their information-seeking behaviour. *Support Care Cancer.* 2003;11(3):162-70.
 22. Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leigh N, et al. Cancer patient preferences for communication of prognosis in the metastatic setting. *J Clin Oncol.* 2004;22(9):1721-30.
 23. Barnett MM. Does it hurt to know the worst?—psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. *Psychooncology.* 2006;15(1):44-55.
 24. Back AL, Arnold RM. Discussing prognosis: "How much do you want to know?" Talking to patients who do not want information or who are ambivalent. *J Clin Oncol.* 2006;24(25):4214-7.
 25. Elkin EB, Kim SHM, Casper ES, Kissane DW, Schrag D. Desire for information and involvement in treatment decisions: Elderly cancer patients' preferences and their physicians' perceptions. *J Clin Oncol.* 2007;25(33):5275-80.
 26. Haes JCMd. Dilemmas in patient centeredness and shared decision making: A case for vulnerability. *Patient Educ Couns.* 2006;62(3):291-8.
 27. Hagerty RG, Butow PN, Ellis PM, Lobb EA, Pendlebury SC, Leigh N, et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. *J Clin Oncol.* 2005;23(6):1278-88.
 28. Han PK. The Need for Uncertainty: A Case for Prognostic Silence. *Perspect Biol Med.* 2016;59(4):567-75.
 29. Butow PN, Dowsett S, Hagerty R, Tattersall MH. Communicating prognosis to patients with metastatic disease: what do they really want to know? *Support Care Cancer.* 2002;10(2):161-8.
 30. Hagerty RG, Butow PN, Ellis PM, Dimitry S, Tattersall MH. Communicating prognosis in cancer care: a systematic review of the literature. *Ann Oncol.* 2005;16(7):1005-53.
 31. Johnston G, Abraham C. Managing awareness: negotiating and coping with a terminal prognosis. *Int J Palliat Nurs.* 2000;6(10):485-94.
 32. Wynn Mon S, Myint Zu WW, Myint Maw M, Win H, Zin Thant K, Yang G, et al. Awareness of and preference for disease prognosis and participation in treatment decisions among advanced cancer patients in Myanmar: Results from the APPROACH study. *Asia Pac J Clin Oncol.* 2021;17(1):149-58.
 33. Mori M, Fujimori M, Ishiki H, Nishi T, Hamano J, Otani H, et al. Adding a wider range and "hope for the best, and prepare for the worst" statement: preferences of patients with cancer for prognostic communication. *Oncologist.* 2019;24(9):e943.
 34. Nwodoh CO, Okoronkwo IL, Nwaneri AC, Nduhuisi I, Chinweuba AU, Iheanacho P. Terminally-ill patients' prognosis information preferences in an African setting: A qualitative descriptive study. *Int J Afr Nurs Sci.* 2020;13:100220.
 35. Bergqvist J, Strang P. Breast Cancer Patients' Preferences for Truth Versus Hope Are Dynamic and Change During Late Lines of Palliative Chemotherapy. *J Pain Symptom Manage.* 2019;57(4):746-52.
 36. Sato RS, Beppu H, Iba N, Sawada A. The meaning of life prognosis disclosure for Japanese cancer patients: a qualitative study of patients' narratives. *Chronic Illn.* 2012;8(3):225-36.
 37. Russell BJ, Ward AM. Deciding what information is necessary: do patients with advanced cancer want to know all the details? *Cancer Manag Res.* 2011;3:191.
 38. ter Hoeven CL, Zandbelt LC, Fransen S, de Haes H, Oort F, Geijsen D, et al. Measuring cancer patients' reasons for their information preference: construction of the Considerations Concerning Cancer Information (CCCI) questionnaire. *Psycho-Oncology.* 2011;20(11):1228-35.
 39. Ong LML, Visser MRM, Van Zuuren FJ, Rietbroek RC, Lammes FB, De Haes JCM. Cancer patients' coping styles and doctor-patient communication. *Psychooncology.* 1999;8(2):155-66.
 40. Schildmann J, Ritter P, Salloch S, Uhl W, Vollmann J. 'One also needs a bit of trust in the doctor...': a qualitative interview study with pancreatic cancer patients about their perceptions and views on information and treatment decision-making. *Ann Oncol.* 2013;24(9):2444-9.
 41. Zafar W, Hafeez H, Jamshed A, Shah MA, Quader A, Yusuf MA. Preferences regarding disclosure of prognosis and end-of-life care: a survey of cancer patients with advanced disease in a lower-middle-income country. *Palliat Med.* 2016;30(7):661-73.
 42. Davey H, Butow P, Armstrong B. Cancer patients' preferences for written prognostic information provided outside the clinical context. *Br J Cancer.* 2003;89(8):1450-6.
 43. Harding R, Simms V, Calanzani N, Higginson IJ, Hall S, Gysels M, et al. If you had less than a year to live, would you want to know? A seven-country European population survey of public preferences for disclosure of poor prognosis. *Psychooncology.* 2013;22(10):2298-305.
 44. Kaplowitz SA, Campo S, Chiu WT. Cancer patients' desires for communication of prognosis information. *Health Commun.* 2002;14(2):221-41.
 45. Henselmans I, Smets EMA, Han PKJ, de Haes H, Laarhoven H. How long do I have? Observational study on communication about life expectancy with advanced cancer patients. *Patient Educ Couns.* 2017;100(10):1820-7.
 46. Douma KF, Koning CC, De Haes HC, Zandbelt LC, Stalpers LJ, Smets EM. Do radiation oncologists tailor information to patients needs? And, if so, does it affect patients? *Acta Oncol.* 2012;51(4):512-20.
 47. Oostendorp LJM, Ottevanger PB, van de Wouwe AJ, Honkoop AH, Los M, van der Graaf WTA, et al. Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences. *J Cancer Educ.* 2016;31(3):443-8.
 48. Hui D, Mo L, Paiva CE. The Importance of Prognostication: Impact of Prognostic Predictions, Disclosures, Awareness, and Acceptance on Patient Outcomes. *Curr Treat Options Oncol.* 2021;22(2):12.
 49. CBO. Zorgmodule Palliatieve Zorg 1.0. 2013.
 50. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ.* 2007;85:867-72.
 51. Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. *Fam Med.* 2004;36(8):588-94.
 52. Franssen MP, Van Schaik TM, Twickler TB, Essink-Bot ML. Applicability of internationally available Health Literacy measures in the Netherlands. *J Health Commun.* 2011;16(sup 3):134-49.
 53. Fagerlin A, Zikmund-Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. *Med Decis Making.* 2007;27(5):672-80.
 54. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European-Organization-For-Research-And-Treatment-Of-Cancer Qlq-C30 - A Quality-Of-Life Instrument for Use in International Clinical-Trials in Oncology. *J Natl Cancer Inst.* 1993;85(5):365-76.
 55. Watson M, Law M, Dossantos M, Greer S, Baruch J, Bliss J. The Mini-Mac - Further Development of the Mental Adjustment to Cancer Scale. *J Psychosoc Oncol.* 1994;12(3):33-46.
 56. Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. *J Pers Soc Psychol.* 1994;67(6):1063-78.
 57. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press; 1983.

58. Sanderman R, Ormel J. De Utrechtse Coping Lijst (UCL): validiteit en betrouwbaarheid. *Gedrag & Gezondheid: Tijdschrift voor Psychologie en Gezondheid*. 1992.
59. Budner S. Intolerance of ambiguity as a personality variable. *J Pers*. 1962;30:29–50.
60. Geller G, Tambor ES, Chase GA, Holtzman NA. Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. *Med Care*. 1993;31(11):989–1001.
61. Hillen MA, Postma R-M, Verdam MG, Smets EM. Development and validation of an abbreviated version of the Trust in Oncologist Scale—the Trust in Oncologist Scale—short form (TiOS-SF). *Support Care Cancer*. 2017;25(3):855–61.
62. Chen Q, Kwok O-M, Luo W, Willson VL. The impact of ignoring a level of nesting structure in multilevel growth mixture models: A Monte Carlo study. *Struct Equ Model*. 2010;17(4):570–89.
63. Shek DT, Ma C. Longitudinal data analyses using linear mixed models in SPSS: concepts, procedures and illustrations. *ScientificWorldJOURNAL*. 2011;11:42–76.
64. Heinrich CJ, Lynn LE Jr. Means and ends: A comparative study of empirical methods for investigating governance and performance. *J Public Adm Res Theory*. 2001;11(1):109–38.
65. Allen M. *The SAGE encyclopedia of communication research methods*: Sage Publications. 2017.
66. Van Stralen K, Dekker F, Zoccali C, Jager K. Measuring agreement, more complicated than it seems. *Nephron Clin Pract*. 2012;120(3):c162–7.
67. Olason DT, Roger D. Optimism, Pessimism and “Fighting spirit”: A new approach to assessing expectancy and adaptation. *Personality Individ Differ*. 2001;31(5):755–68.
68. Besseling J, Reitsma J, Van Erkelens JA, Schepens MH, Siroen MP, Ziedses des Plantes CM, et al. Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study. *Cancers*. 2021;13(1):145.
69. Chen CH, Wen FH, Hou MM, Hsieh CH, Chou WC, Chen JS, et al. Transitions in Prognostic Awareness Among Terminally Ill Cancer Patients in Their Last 6 Months of Life Examined by Multi-State Markov Modeling. *Oncologist*. 2017;22(9):1135–42.
70. Hinton J. The progress of awareness and acceptance of dying assessed in cancer patients and their caring relatives. *PalliatMed*. 1999;13(1):19–35.
71. Clayton JM, Hancock KM, Butow PN, Tattersall MH, Currow DC, Adler J, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. *Med J Aust*. 2007;186(12 Suppl):S77 (S9, S83–108).
72. van der Velden N, van der Kleij M, Lehmann V, Smets E, Stouthard J, Henselmans I, et al. Communication about Prognosis during Patient-Initiated Second Opinion Consultations in Advanced Cancer Care: An Observational Qualitative Analysis. *Int J Environ Res Public Health*. 2021;18(11):5694.
73. Deckx L, Thomas HR, Sieben NA, Foster MM, Mitchell GK. General practitioners' practical approach to initiating end-of-life conversations: a qualitative study. *Fam Pract*. 2020;37(3):401–5.
74. Rodriguez KL, Gambino FJ, Butow P, Hagerly R, Arnold RM. Pushing up daisies: implicit and explicit language in oncologist-patient communication about death. *Support Care Cancer*. 2007;15(2):153–61.
75. Walczak A, Mazer B, Butow PN, Tattersall MHN, Clayton JM, Davidson PM, et al. A question prompt list for patients with advanced cancer in the final year of life: Development and cross-cultural evaluation. *Palliat Med*. 2013;27(8):779–88.
76. van der Velden NC, Meijers MC, Han PK, van Laarhoven HW, Smets EM, Henselmans I. The effect of prognostic communication on patient outcomes in palliative cancer care: a systematic review. *Curr Treat Options Oncol*. 2020;21(5):1–38.
77. Fletcher K, Prigerson HG, Paulk E, Temel J, Finlay E, Marr L, et al. Gender differences in the evolution of illness understanding among patients with advanced cancer. *J Support Oncol*. 2013;11(3):126.
78. Fletcher KM, Prigerson HG, Maciejewski PK. Women know, and men wish they knew, prognostic information in advanced cancer. *J Clin Oncol*. 2012;30(15_suppl):9037.
79. Hofmann JC, Wenger NS, Davis RB, Teno J, Connors AF, Desbiens N, et al. Patient preferences for communication with physicians about end-of-life decisions. *Ann Intern Med*. 1997;127(1):1–12.
80. Franssen SJ, Lagarde SM, Van Werven JR, Smets EMA, Tran KTC, Plukker JTM, et al. Psychological factors and preferences for communicating prognosis in esophageal cancer patients. *Psycho-Oncology*. 2009;18(11):199–207.
81. Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. *BMJ*. 2012;345:e6572.
82. Westendorp J, Evers AW, Stouthard JM, Budding J, van der Wall E, Plum NM, et al. Mind your words: Oncologists' communication that potentially harms patients with advanced cancer: A survey on patient perspectives. *Cancer*. 2022;128(5):1133–40.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

